Following questions about the integrity of clinical trial data, regulators in Europe are taking a second look at Tavneos (avacopan), an oral therapy approved for ANCA-associated vasculitis (AAV). In a press release, the European Medicines Agency (EMA) announced that it “will now review all available data to…
Discussion
Living with a chronic illness like ANCA vasculitis teaches us many things, often lessons we never asked to learn. One of the most powerful lessons I’ve discovered is the importance of holding on loosely — to the good days, the tough days, and everything in between. When I grip…
Rituximab is at least as effective as cyclophosphamide in inducing remission in people with ANCA-associated vasculitis (AAV), and it may offer a safer, more targeted option for many patients, according to a review study. “These findings reinforce the evolving role of rituximab…
Becoming educated and informed about ANCA vasculitis is a good first step. Here you’ll find general information such as the diagnosis, symptoms, and causes.
It helps to know others have been where you are now. Here’s a collection of our columnists’ words of wisdom to help you along on your ANCA vasculitis journey.
There is no cure for ANCA vasculitis yet, but here you can find more information about current approved treatments, as well as experimental treatments that are in the pipeline.
Get regular updates to your inbox.
